BioMarker Strategies has developed the recently patented SnapPath® Cancer Diagnostics System to address the reality that available biomarker tests for solid tumors primarily rely on dead fixed-tissue samples. SnapPath® purifies-protects live solid tumor cell populations for exposure to targeted therapies on the system, and captures dynamic functional information about cell signaling pathways that is far more predictive of individual response.